# pathway_0125

[All questions and paired results](../README.md) · [Method](../METHOD.md) · [Source credits](../THIRD_PARTY_NOTICES.md)

**Task:** `pathway`  
**Author expected answer:** **B** — Secondary metabolite biosynthesis. .

| Reviewer | Expected-answer support | Reasoning / lookup | Validity |
|---|---|---|---|
| GPT-6 Luna | supported | lookup-dependent | valid_review |
| Qwen3.8-Flash-Next-NVFP4 | supported | lookup-dependent | valid_review |

**Paired comparison:** key agree; reasoning agree. Agreement is not proof of correctness. These are separate AI judgments, with no forced consensus or changed key.

## Complete original question

```text
[Protein Sequence]
MGTTERESDPIAALILDRLSCTEYACSSLSRVNGGLMNFIYRGTLSRPLPDGATTVIVKHAEEYLSGIEGLSLSTYRSVIAAITLSFGYCVMDVESVQTNRYCVALDEVEVAVPRVYKFDAESNTQILEDITGYITVCEFLTSRCTQSTSPAFTTRLGFRLGSWLGGLHAWGEGRSPAEIIGGVEENQEAQDGSFDFFYGNPVRRVEQFPHLLGDCKEVLEQIRDRAAREQKSRTGEKFGFVHGDILSRKSVLIPGDSVTRDQHLRFVIIDWELSQYECHFRECGEVLGDLYLLKRFQDIDGAMSIIQGFLEGYPPLNEDAIFRTAIYLGLFLLANEVTLSTDYPKQQIEDFVILARDLVLAGWHKDRETLAKTVFGPVFFRAMN

[Multiple Choices]
A. Alkaloid biosynthesis
B. Secondary metabolite biosynthesis. .
C. xylan degradation. .
D. Capsule biogenesis
```

<details>
<summary>Original system instructions, verbatim</summary>

```text
You are an excellent scientist. Analyze the provided protein-related task carefully and choose the correct answer from the multiple-choice options.

The current task is about Protein Pathway Prediction, which is to predict the primary metabolic or signaling pathway in which a given protein functions. Biological pathways are series of chemical reactions occurring within a cell that are essential for life. Based on the protein's amino acid sequence, you should identify the most relevant pathway from the given options.. The inputs provided by the user for this task include:

* Protein Sequence: The amino acid sequence of the protein.
* Multiple Choices: Candidate answers for the protein-related question.

Please think step-by-step about this problem:
1. Analyze the protein sequence carefully.
2. Consider the biological context and function.
3. Evaluate each multiple-choice option.
4. Provide your reasoning process.
5. Finally, give your answer.

Provide your response in the following format:
1. reasoning: [Your detailed reasoning here]
2. answer: Your final answer, which should be "A", "B", "C" or "D".
```

</details>

## GPT-6 Luna

**Saved status:** `valid_review`.

### Expected-answer support: supported

> The sequence-matched historical UniProt entry assigns this protein to secondary metabolite biosynthesis and cites a paper whose reference includes pathway and function evidence. This supports B as a database annotation, though the cited study was not independently examined here.

Citations as saved: [H2](#evidence-h2), [H3](#evidence-h3).

### Reasoning versus lookup: lookup-dependent

**Discriminating biological argument**

> The sequence is not accompanied by biological context identifying its biosynthetic cluster or product. The choices do not provide a sequence-derived clue that uniquely assigns this protein to the FR901483 pathway.


**Missing item-specific fact**

> The protein-specific pathway assignment, available here from the matched UniProt record and its cited study, is absent from the model input.


**Reason**

> Inferring that this enzyme participates in secondary metabolism rather than a primary pathway requires protein-specific functional or pathway information; the sequence alone does not meaningfully distinguish the options.


### Question ambiguity

**Multiple defensible options, exactly as saved:**

```json
[
  "A",
  "B"
]
```

> Alkaloid biosynthesis is a category of secondary metabolite biosynthesis, so the options overlap. The supplied evidence supports the broader B annotation but does not establish whether the relevant product also warrants the more specific A label.


### Important caveats

- The historical record matches the supplied sequence, but the author's exact source snapshot is unknown.
- The pathway assignment is a cited database annotation; the primary study was not independently validated here.

<details>
<summary>Complete saved parsed visible review</summary>

```json
{
  "answerability_check": {
    "discriminating_biological_argument": "The sequence is not accompanied by biological context identifying its biosynthetic cluster or product. The choices do not provide a sequence-derived clue that uniquely assigns this protein to the FR901483 pathway.",
    "judgment": "lookup_or_memorization_dependent",
    "missing_item_specific_fact": "The protein-specific pathway assignment, available here from the matched UniProt record and its cited study, is absent from the model input.",
    "reason": "Inferring that this enzyme participates in secondary metabolism rather than a primary pathway requires protein-specific functional or pathway information; the sequence alone does not meaningfully distinguish the options."
  },
  "case_id": "pathway_0125",
  "expected_answer_check": {
    "evidence_ids": [
      "H2",
      "H3"
    ],
    "judgment": "supported",
    "reason": "The sequence-matched historical UniProt entry assigns this protein to secondary metabolite biosynthesis and cites a paper whose reference includes pathway and function evidence. This supports B as a database annotation, though the cited study was not independently examined here."
  },
  "important_caveats": [
    "The historical record matches the supplied sequence, but the author's exact source snapshot is unknown.",
    "The pathway assignment is a cited database annotation; the primary study was not independently validated here."
  ],
  "question_ambiguity": {
    "multiple_defensible_options": [
      "A",
      "B"
    ],
    "reason": "Alkaloid biosynthesis is a category of secondary metabolite biosynthesis, so the options overlap. The supplied evidence supports the broader B annotation but does not establish whether the relevant product also warrants the more specific A label."
  }
}
```

</details>

<details>
<summary>Exact saved visible final text</summary>

```text
{
  "case_id": "pathway_0125",
  "expected_answer_check": {
    "judgment": "supported",
    "reason": "The sequence-matched historical UniProt entry assigns this protein to secondary metabolite biosynthesis and cites a paper whose reference includes pathway and function evidence. This supports B as a database annotation, though the cited study was not independently examined here.",
    "evidence_ids": ["H2", "H3"]
  },
  "answerability_check": {
    "judgment": "lookup_or_memorization_dependent",
    "discriminating_biological_argument": "The sequence is not accompanied by biological context identifying its biosynthetic cluster or product. The choices do not provide a sequence-derived clue that uniquely assigns this protein to the FR901483 pathway.",
    "missing_item_specific_fact": "The protein-specific pathway assignment, available here from the matched UniProt record and its cited study, is absent from the model input.",
    "reason": "Inferring that this enzyme participates in secondary metabolism rather than a primary pathway requires protein-specific functional or pathway information; the sequence alone does not meaningfully distinguish the options."
  },
  "question_ambiguity": {
    "multiple_defensible_options": ["A", "B"],
    "reason": "Alkaloid biosynthesis is a category of secondary metabolite biosynthesis, so the options overlap. The supplied evidence supports the broader B annotation but does not establish whether the relevant product also warrants the more specific A label."
  },
  "important_caveats": [
    "The historical record matches the supplied sequence, but the author's exact source snapshot is unknown.",
    "The pathway assignment is a cited database annotation; the primary study was not independently validated here."
  ]
}
```

</details>

## Qwen3.8-Flash-Next-NVFP4

**Saved status:** `valid_review`.

### Expected-answer support: supported

> UniProt entry A0A7T8F1J6 (Phosphotransferase FrzJ, EC 2.7.1.-) is explicitly annotated with PATHWAY: 'Secondary metabolite biosynthesis' under experimental evidence code ECO:0000269 from PubMed:33372776 (Zhang et al., JACS 2021, on biosynthesis of the immunosuppressant (-)-FR901483). FR901483 is a cyclic-peptide natural product, a secondary metabolite, and FrzJ is a phosphotransferase within its biosynthetic gene cluster. The sequence matches the benchmark exactly (385 AA, SHA-256 identical).

Citations as saved: [C1](#evidence-c1), [C4](#evidence-c4), [C5](#evidence-c5), [C6](#evidence-c6), [H1](#evidence-h1), [H2](#evidence-h2), [H3](#evidence-h3).

### Reasoning versus lookup: lookup-dependent

**Discriminating biological argument**

> From the sequence one can identify phosphotransferase/kinase-like motifs (e.g., 'HGD', 'GDSVTRD', 'WLGGLHAWGEGRSPAE') consistent with a biosynthetic gene-cluster enzyme, which helps rule out xylan degradation (C: glycoside hydrolases) and capsule biogenesis (D: glycosyltransferases/polysaccharide machinery). However, the critical distinction between option A (alkaloid biosynthesis) and option B (secondary metabolite biosynthesis) requires knowing that FR901483 is a cyclic-peptide natural product and NOT an alkaloid. Without that item-specific fact, a solver could reasonably argue for A, since alkaloid biosynthesis is itself a subtype of secondary metabolite biosynthesis and phosphotransferases do appear in some alkaloid pathways.


**Missing item-specific fact**

> The identity of the specific metabolite (FR901483, a cyclic peptide immunosuppressant) and its classification as a non-alkaloid secondary metabolite, which is required to exclude option A in favor of the broader category B.


**Reason**

> General sequence analysis identifies a phosphotransferase, narrowing choices to biosynthetic pathways (A or B), but the final A-vs-B discrimination depends on knowing the metabolite class of the specific compound synthesized by this cluster member. This is a protein-specific annotation fact not derivable from the sequence alone.


### Question ambiguity

**Multiple defensible options, exactly as saved:**

```json
[
  "A",
  "B"
]
```

> Option B ('Secondary metabolite biosynthesis') is a broad category that encompasses alkaloid biosynthesis. If the protein were involved in any alkaloid pathway, both A and B would be simultaneously correct. The question is only unambiguous because FR901483 happens not to be an alkaloid, an item-specific fact not stated in the prompt. Additionally, the trailing '. .' in options B and C is a formatting artifact but does not alter meaning.


### Important caveats

- The UniProt pathway annotation carries ECO:0000269 (experimental), indicating the pathway assignment was supported by experimental work in the cited JACS 2021 paper, not merely by computational inference.
- The identity of the sequence as A0A7T8F1J6 was inferred by the reviewer from dataset metadata; the evaluated model received only the raw 385-aa sequence with no accession or organism information.
- Options B and C contain trailing '. .' punctuation, likely a data-construction artifact; this does not affect semantic interpretation.
- The author source snapshot is unknown; the historical Swiss-Prot record (entry version 6, released 2026-01-28) already contained the same pathway annotation, so the key was available before the 2026-05-07 cutoff.

<details>
<summary>Complete saved parsed visible review</summary>

```json
{
  "answerability_check": {
    "discriminating_biological_argument": "From the sequence one can identify phosphotransferase/kinase-like motifs (e.g., 'HGD', 'GDSVTRD', 'WLGGLHAWGEGRSPAE') consistent with a biosynthetic gene-cluster enzyme, which helps rule out xylan degradation (C: glycoside hydrolases) and capsule biogenesis (D: glycosyltransferases/polysaccharide machinery). However, the critical distinction between option A (alkaloid biosynthesis) and option B (secondary metabolite biosynthesis) requires knowing that FR901483 is a cyclic-peptide natural product and NOT an alkaloid. Without that item-specific fact, a solver could reasonably argue for A, since alkaloid biosynthesis is itself a subtype of secondary metabolite biosynthesis and phosphotransferases do appear in some alkaloid pathways.",
    "judgment": "lookup_or_memorization_dependent",
    "missing_item_specific_fact": "The identity of the specific metabolite (FR901483, a cyclic peptide immunosuppressant) and its classification as a non-alkaloid secondary metabolite, which is required to exclude option A in favor of the broader category B.",
    "reason": "General sequence analysis identifies a phosphotransferase, narrowing choices to biosynthetic pathways (A or B), but the final A-vs-B discrimination depends on knowing the metabolite class of the specific compound synthesized by this cluster member. This is a protein-specific annotation fact not derivable from the sequence alone."
  },
  "case_id": "pathway_0125",
  "expected_answer_check": {
    "evidence_ids": [
      "C1",
      "C4",
      "C5",
      "C6",
      "H1",
      "H2",
      "H3"
    ],
    "judgment": "supported",
    "reason": "UniProt entry A0A7T8F1J6 (Phosphotransferase FrzJ, EC 2.7.1.-) is explicitly annotated with PATHWAY: 'Secondary metabolite biosynthesis' under experimental evidence code ECO:0000269 from PubMed:33372776 (Zhang et al., JACS 2021, on biosynthesis of the immunosuppressant (-)-FR901483). FR901483 is a cyclic-peptide natural product, a secondary metabolite, and FrzJ is a phosphotransferase within its biosynthetic gene cluster. The sequence matches the benchmark exactly (385 AA, SHA-256 identical)."
  },
  "important_caveats": [
    "The UniProt pathway annotation carries ECO:0000269 (experimental), indicating the pathway assignment was supported by experimental work in the cited JACS 2021 paper, not merely by computational inference.",
    "The identity of the sequence as A0A7T8F1J6 was inferred by the reviewer from dataset metadata; the evaluated model received only the raw 385-aa sequence with no accession or organism information.",
    "Options B and C contain trailing '. .' punctuation, likely a data-construction artifact; this does not affect semantic interpretation.",
    "The author source snapshot is unknown; the historical Swiss-Prot record (entry version 6, released 2026-01-28) already contained the same pathway annotation, so the key was available before the 2026-05-07 cutoff."
  ],
  "question_ambiguity": {
    "multiple_defensible_options": [
      "A",
      "B"
    ],
    "reason": "Option B ('Secondary metabolite biosynthesis') is a broad category that encompasses alkaloid biosynthesis. If the protein were involved in any alkaloid pathway, both A and B would be simultaneously correct. The question is only unambiguous because FR901483 happens not to be an alkaloid, an item-specific fact not stated in the prompt. Additionally, the trailing '. .' in options B and C is a formatting artifact but does not alter meaning."
  }
}
```

</details>

<details>
<summary>Exact saved visible final text</summary>

```text


{
  "case_id": "pathway_0125",
  "expected_answer_check": {
    "judgment": "supported",
    "reason": "UniProt entry A0A7T8F1J6 (Phosphotransferase FrzJ, EC 2.7.1.-) is explicitly annotated with PATHWAY: 'Secondary metabolite biosynthesis' under experimental evidence code ECO:0000269 from PubMed:33372776 (Zhang et al., JACS 2021, on biosynthesis of the immunosuppressant (-)-FR901483). FR901483 is a cyclic-peptide natural product, a secondary metabolite, and FrzJ is a phosphotransferase within its biosynthetic gene cluster. The sequence matches the benchmark exactly (385 AA, SHA-256 identical).",
    "evidence_ids": ["C1", "C4", "C5", "C6", "H1", "H2", "H3"]
  },
  "answerability_check": {
    "judgment": "lookup_or_memorization_dependent",
    "discriminating_biological_argument": "From the sequence one can identify phosphotransferase/kinase-like motifs (e.g., 'HGD', 'GDSVTRD', 'WLGGLHAWGEGRSPAE') consistent with a biosynthetic gene-cluster enzyme, which helps rule out xylan degradation (C: glycoside hydrolases) and capsule biogenesis (D: glycosyltransferases/polysaccharide machinery). However, the critical distinction between option A (alkaloid biosynthesis) and option B (secondary metabolite biosynthesis) requires knowing that FR901483 is a cyclic-peptide natural product and NOT an alkaloid. Without that item-specific fact, a solver could reasonably argue for A, since alkaloid biosynthesis is itself a subtype of secondary metabolite biosynthesis and phosphotransferases do appear in some alkaloid pathways.",
    "missing_item_specific_fact": "The identity of the specific metabolite (FR901483, a cyclic peptide immunosuppressant) and its classification as a non-alkaloid secondary metabolite, which is required to exclude option A in favor of the broader category B.",
    "reason": "General sequence analysis identifies a phosphotransferase, narrowing choices to biosynthetic pathways (A or B), but the final A-vs-B discrimination depends on knowing the metabolite class of the specific compound synthesized by this cluster member. This is a protein-specific annotation fact not derivable from the sequence alone."
  },
  "question_ambiguity": {
    "multiple_defensible_options": ["A", "B"],
    "reason": "Option B ('Secondary metabolite biosynthesis') is a broad category that encompasses alkaloid biosynthesis. If the protein were involved in any alkaloid pathway, both A and B would be simultaneously correct. The question is only unambiguous because FR901483 happens not to be an alkaloid, an item-specific fact not stated in the prompt. Additionally, the trailing '. .' in options B and C is a formatting artifact but does not alter meaning."
  },
  "important_caveats": [
    "The UniProt pathway annotation carries ECO:0000269 (experimental), indicating the pathway assignment was supported by experimental work in the cited JACS 2021 paper, not merely by computational inference.",
    "The identity of the sequence as A0A7T8F1J6 was inferred by the reviewer from dataset metadata; the evaluated model received only the raw 385-aa sequence with no accession or organism information.",
    "Options B and C contain trailing '. .' punctuation, likely a data-construction artifact; this does not affect semantic interpretation.",
    "The author source snapshot is unknown; the historical Swiss-Prot record (entry version 6, released 2026-01-28) already contained the same pathway annotation, so the key was available before the 2026-05-07 cutoff."
  ]
}
```

</details>

## Existing project source checks of Luna’s review

The notes below were prepared for specific claims in the Luna review. They are not independent validation of Qwen’s claims, expert adjudication, or replacement verdicts.

## Project source-check notes

These project-authored, AI-assisted checks assess specific source claims. They are not expert adjudication and do not replace Luna’s saved review or the author key.

No additional case-specific project note was recorded. Citation membership checks do not establish that every scientific argument is correct.

## Reviewer-only source evidence

**Both reviewers received this source evidence separately from the original question. It was not available to the original evaluated model.** Source support and reasoning from the original sequence/choices are distinct assessments.

**Accession:** `A0A7T8F1J6` (recovered from dataset image-path metadata, not original question text).  
**Sequence applicability:** historical matched; current matched.  
**Historical cutoff:** 2026-05-07; archived entry version 6. Exact author snapshot unknown.

- All evidence and source identity in this section are reviewer-only and were absent from the evaluated model input.
- UniProt annotations may be experimental, computational, or transferred by similarity; evidence codes and qualifiers are retained.
- The 2026-05-07 cutoff approximates the pinned repository date; the author data-construction date and exact source snapshot remain unknown.
- Selected source fields are excerpts; missing annotation is not evidence of falsehood. Primary papers were not comprehensively retrieved or independently validated.

### Evidence C1

[UniProtKB current entry](https://rest.uniprot.org/uniprotkb/A0A7T8F1J6.json)  
**Locator:** `/primaryAccession`  
**Scope:** current snapshot; actual author source snapshot unknown.  
**Sequence comparison:** matched.  
**Retrieved:** 2026-11-01T06:24:50.675828+00:00.  

```json
"A0A7T8F1J6"
```

Source SHA-256: `c8973cce1ed0e2fab533a94cb1b8b2dc4cfa81417a13963fef0bf5204d549a83`.

### Evidence C4

[UniProtKB current entry](https://rest.uniprot.org/uniprotkb/A0A7T8F1J6.json)  
**Locator:** `/proteinDescription`  
**Scope:** current snapshot; actual author source snapshot unknown.  
**Sequence comparison:** matched.  
**Retrieved:** 2026-11-01T06:24:50.675828+00:00.  

```json
{"alternativeNames":[{"fullName":{"evidences":[{"evidenceCode":"ECO:0000303","id":"33372776","source":"PubMed"}],"value":"FR901483 biosynthesis clusters protein J"}}],"recommendedName":{"ecNumbers":[{"evidences":[{"evidenceCode":"ECO:0000269","id":"33372776","source":"PubMed"}],"value":"2.7.1.-"}],"fullName":{"evidences":[{"evidenceCode":"ECO:0000303","id":"33372776","source":"PubMed"}],"value":"Phosphotransferase FrzJ"}}}
```

Source SHA-256: `c8973cce1ed0e2fab533a94cb1b8b2dc4cfa81417a13963fef0bf5204d549a83`.

### Evidence C5

[UniProtKB current entry](https://rest.uniprot.org/uniprotkb/A0A7T8F1J6.json)  
**Locator:** `/comments/2`  
**Scope:** current snapshot; actual author source snapshot unknown.  
**Sequence comparison:** matched.  
**Retrieved:** 2026-11-01T06:24:50.675828+00:00.  

```json
{"commentType":"PATHWAY","texts":[{"evidences":[{"evidenceCode":"ECO:0000269","id":"33372776","source":"PubMed"}],"value":"Secondary metabolite biosynthesis"}]}
```

Source SHA-256: `c8973cce1ed0e2fab533a94cb1b8b2dc4cfa81417a13963fef0bf5204d549a83`.

### Evidence C6

[UniProtKB current entry](https://rest.uniprot.org/uniprotkb/A0A7T8F1J6.json)  
**Locator:** `/references/0`  
**Scope:** current snapshot; actual author source snapshot unknown.  
**Sequence comparison:** matched.  
**Retrieved:** 2026-11-01T06:24:50.675828+00:00.  

```json
{"citation":{"authors":["Zhang Z.","Tamura Y.","Tang M.","Qiao T.","Sato M.","Otsu Y.","Sasamura S.","Taniguchi M.","Watanabe K.","Tang Y."],"citationCrossReferences":[{"database":"PubMed","id":"33372776"},{"database":"DOI","id":"10.1021/jacs.0c12352"}],"citationType":"journal article","firstPage":"132","id":"33372776","journal":"J. Am. Chem. Soc.","lastPage":"136","publicationDate":"2021","title":"Biosynthesis of the Immunosuppressant (-)-FR901483.","volume":"143"},"referenceComments":[{"type":"STRAIN","value":"11231"}],"referenceNumber":1,"referencePositions":["NUCLEOTIDE SEQUENCE [GENOMIC DNA]","FUNCTION","CATALYTIC ACTIVITY","PATHWAY"]}
```

Source SHA-256: `c8973cce1ed0e2fab533a94cb1b8b2dc4cfa81417a13963fef0bf5204d549a83`.

### Evidence H1

[UniSave archived UniProt entry](https://rest.uniprot.org/unisave/A0A7T8F1J6?format=txt&versions=6)  
**Locator:** `lines 1-13`  
**Scope:** record released no later than 2026-05-07; actual author source snapshot unknown.  
**Sequence comparison:** matched.  
**Entry / sequence version:** 6 / 1.  
**Retrieved:** 2026-11-01T06:27:33.489845+00:00.  

```text
ID   FRZJ_CLASX              Reviewed;         385 AA.
AC   A0A7T8F1J6;
DT   18-JUN-2025, integrated into UniProtKB/Swiss-Prot.
DT   02-JUN-2021, sequence version 1.
DT   28-JAN-2026, entry version 6.
DE   RecName: Full=Phosphotransferase FrzJ {ECO:0000303|PubMed:33372776};
DE            EC=2.7.1.- {ECO:0000269|PubMed:33372776};
DE   AltName: Full=FR901483 biosynthesis clusters protein J {ECO:0000303|PubMed:33372776};
GN   Name=FrzJ {ECO:0000303|PubMed:33372776};
OS   Cladobotryum sp.
OC   Eukaryota; Fungi; Dikarya; Ascomycota; Pezizomycotina; Sordariomycetes;
OC   Hypocreomycetidae; Hypocreales; Hypocreaceae; Cladobotryum.
OX   NCBI_TaxID=2040732;
```

Source SHA-256: `a3c8964073737ce02aefe4d7b1c7dc5803711f2bade9edceed980e3bae3f99f8`.

### Evidence H2

[UniSave archived UniProt entry](https://rest.uniprot.org/unisave/A0A7T8F1J6?format=txt&versions=6)  
**Locator:** `lines 14-22`  
**Scope:** record released no later than 2026-05-07; actual author source snapshot unknown.  
**Sequence comparison:** matched.  
**Entry / sequence version:** 6 / 1.  
**Retrieved:** 2026-11-01T06:27:33.489845+00:00.  

```text
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, CATALYTIC ACTIVITY, AND
RP   PATHWAY.
RC   STRAIN=11231;
RX   PubMed=33372776; DOI=10.1021/jacs.0c12352;
RA   Zhang Z., Tamura Y., Tang M., Qiao T., Sato M., Otsu Y., Sasamura S.,
RA   Taniguchi M., Watanabe K., Tang Y.;
RT   "Biosynthesis of the Immunosuppressant (-)-FR901483.";
RL   J. Am. Chem. Soc. 143:132-136(2021).
```

Source SHA-256: `a3c8964073737ce02aefe4d7b1c7dc5803711f2bade9edceed980e3bae3f99f8`.

### Evidence H3

[UniSave archived UniProt entry](https://rest.uniprot.org/unisave/A0A7T8F1J6?format=txt&versions=6)  
**Locator:** `lines 61-62`  
**Scope:** record released no later than 2026-05-07; actual author source snapshot unknown.  
**Sequence comparison:** matched.  
**Entry / sequence version:** 6 / 1.  
**Retrieved:** 2026-11-01T06:27:33.489845+00:00.  

```text
CC   -!- PATHWAY: Secondary metabolite biosynthesis.
CC       {ECO:0000269|PubMed:33372776}.
```

Source SHA-256: `a3c8964073737ce02aefe4d7b1c7dc5803711f2bade9edceed980e3bae3f99f8`.

---

Original question/key: [pinned source](https://github.com/Rongdingyi/LiveProteinBench/blob/8b9710932511f816651fc1a7e8a1bc85c3c77767/dataset/QA/pathway.json), zero-based source row 125. © 2026 LiveProteinBench contributors; [CC BY 4.0](https://huggingface.co/datasets/LiveProteinBench/LiveProteinBench/blob/8428f64e33d53330f7745376d9c45de2d2c37eaf/LICENSE). UniProt and Gene Ontology credits are retained in [source notices](../THIRD_PARTY_NOTICES.md).
